FDA misses decision deadline for Savara’s autoimmune PAP treatment
The FDA missed its November 22, 2026 deadline for Savara’s nebulized molgramostim, leaving the application under review with no new decision date. Savara says the agency identified no safety, efficacy or manufacturing concerns; approval timing remains uncertain despite substantial unmet need.
Sources (2)
Updated Nov 21, 2026